Sinovac Biotech Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sinovac Biotech Ltd.
Some of China's makers of COVID-19 antivirals are fast-tracking neutralizing antibodies and peptide fusion inhibitors in clinical trials, while vaccine developers are embroiled in a tougher situation against the mutating coronavirus.
The past couple of years have generated important growth for the pharma industry thanks to its drugs and vaccines for COVID-19. But with the IRA, high inflation, rising interest rates and chilly public markets, biopharma faces challenges this year. Here, we summarize key messages from In Vivo’s Outlook 2023.
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.
- In Vitro Diagnostics
- Drug Delivery
- Implantable Devices
- Monitoring Equipment & Devices
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Beijing Kexing Bioproducts
- Sinovac Dalian Vaccine Technology Co., Ltd.
- Sinovac (Cayman) Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.